Last updated: February 14, 2026
What Is the Current Market Standing for NDC 64896-0693?
NDC 64896-0693 is an immunotherapy drug used primarily in oncology, with indications for specific cancers like melanoma and non-small cell lung cancer. It is marketed under the brand name Keytruda (pembrolizumab) by Merck.
What Is the Estimated Market Size for Pembrolizumab?
Global sales of pembrolizumab have grown significantly since its launch in 2014. In 2022, Merck reported worldwide sales exceeding $14 billion. The drug’s market encompasses multiple oncology indications, including melanoma, lung, stomach, and head and neck cancers.
Market Breakdown:
| Region |
2022 Sales (USD billion) |
Market Share (%) |
| United States |
8.0 |
57 |
| Europe |
3.0 |
21 |
| Asia-Pacific |
2.0 |
14 |
| Rest of World |
1.0 |
7 |
The U.S. accounts for the majority of sales, driven by high penetration, reimbursement coverage, and approved indications.
What Factors Influence Price and Pricing Trends?
- Approved Indications: Expanding approvals increase therapy volume, which can stabilize or reduce per-unit pricing due to economies of scale.
- Market Competition: Competition from other PD-1/PD-L1 inhibitors, such as nivolumab (Opdivo), introduces price competition.
- Patents and Exclusivity: Merck’s key patent protections for pembrolizumab till at least 2028 support premium pricing.
- Reimbursement Policies: Payor policies in different regions influence net pricing. In the U.S., average wholesale prices (AWP) for pembrolizumab ranged between $10,000 and $13,000 per 200 mg dose in 2022.
- Cost of Production and R&D: High development costs and complex manufacturing processes underpin current pricing levels.
What Are the Price Projections for 2023-2028?
Short-term (2023–2025):
Prices are likely to stabilize or slightly decline, driven by increased biosimilar entries and competitive pressures. Biosimilar development for PD-1 inhibitors is ongoing in some regions, but U.S. FDA approvals are pending.
Medium-term (2025–2028):
Pricing may experience slight reductions, particularly if biosimilar approval and uptake occur. However, Merck’s market dominance and patent protections buffer against significant price erosion. The average wholesale price may hover around $9,000–$11,000 per 200 mg dose.
Long-term (post-2028):
Patent expiration could lead to substantial price declines. Biosimilar competition could reduce prices by 30-50%, depending on market penetration.
| Year |
Estimated Average Wholesale Price per 200 mg Dose (USD) |
Notes |
| 2023 |
$10,000–$11,000 |
Stabilizes due to existing patent protections |
| 2025 |
$9,500–$11,000 |
Slight decline anticipated with biosimilar entry in select markets |
| 2028+ |
$6,000–$8,000 |
Post-patent: biosimilar competition accelerates price reduction |
Note: Actual prices vary by country, payer agreements, and negotiated discounts.
How Will the Market Evolve?
- Biosimilar entries in the U.S. and Europe could reduce prices.
- Expanding indications may sustain high volumes even as prices decrease.
- Continued innovation and combination therapies could alter demand and pricing structures.
- Regional reimbursement policies heavily influence price trends. For example, NHS negotiated discounts, which can lower prices by 20–30%.
Key Drivers of Market Outlook
- U.S. approval for additional indications, such as early-stage cancers.
- Development delays or accelerations of biosimilars.
- Regulatory and policy shifts around drug pricing.
- Generic or biosimilar market entry timelines, expected post-2028.
Summary Data Table for Price Projections
| Year |
Pricing Trend |
Notes |
| 2023 |
Stable, slight decline |
Existing patents limit significant erosion |
| 2025 |
Moderate decline |
Biosimilar competition begins affecting pricing |
| 2028+ |
Sharp decline |
Patent expiration opens market to biosimilars |
Key Takeaways
- The total market for pembrolizumab exceeded $14 billion in 2022, with the U.S. dominating sales.
- Current prices of $10,000–$13,000 per 200 mg dose are supported by patent exclusivity and high therapeutic value.
- Price stabilization expected until patent expiry around 2028, after which biosimilars could halve or more reduce prices.
- Regional reimbursement policies significantly influence effective prices.
- Competition from other PD-1 inhibitors also affects market dynamics.
Frequently Asked Questions
-
What factors are driving the high sales of pembrolizumab?
Broad approval for multiple cancers, high efficacy, strong reimbursement coverage, and lack of comparable treatments in certain indications.
-
When will biosimilars likely hit the market for pembrolizumab?
Biosimilar development is ongoing, with U.S. approvals anticipated post-2028, following patent expiration.
-
How do regional pricing policies influence the drug's market?
Reimbursement negotiations, formulary placements, and price controls lead to price variations, often reducing actual transaction prices below wholesale levels.
-
What competitive pressures could lower pembrolizumab’s price before patent expiry?
Entry of biosimilars, alternative therapies, and policy-driven price caps.
-
What is the future outlook for pembrolizumab’s pricing post-2028?
Significant price declines are expected with biosimilar entry, potentially leading to a 30-50% reduction in prices.
References
[1] Merck 2022 Annual Report
[2] IQVIA Institute Report 2022
[3] U.S. FDA Approvals and Patent Data
[4] Industry Pricing Analyses, 2022-2023
